Kanagawa Valsartan Trial (KVT): Effects of Valsartan on Renal and Cardiovascular Disease

PHASE4CompletedINTERVENTIONAL
Enrollment

312

Participants

Timeline

Start Date

February 28, 2003

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions
Chronic Kidney DiseaseHypertension
Interventions
DRUG

valsartan

valsartan, dosage from 20mg to 180mg, once or twice a day plus conventional antihypertensive drugs

DRUG

Conventional antihypertensive drugs

Conventional antihypertensive drugs including calcium channel blockers, diuretics, angiotensin converting enzyme inhibitors and/or beta-blockers

Trial Locations (1)

216-8511

St. Marianna University School of Medicine, Kawasaki

All Listed Sponsors
collaborator

Tokai University

OTHER

collaborator

Yokohama City University

OTHER

collaborator

Showa University

OTHER

collaborator

Kitasato University

OTHER

collaborator

St. Marianna University School of Medicine

OTHER

lead

KVT-Study Group

OTHER

NCT00190580 - Kanagawa Valsartan Trial (KVT): Effects of Valsartan on Renal and Cardiovascular Disease | Biotech Hunter | Biotech Hunter